STAT10h
Pharmalittle: We’re reading about possible HIV prevention cuts, FDA warning an African drugmaker, and more
The U.S. Health and Human Services Department is weighing plans to drastically cut federal government funding for domestic ...
Fierce Healthcare2d
HHS may cut HIV prevention efforts at the CDC. Advocates fear changes will spike infections
The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...
Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally
So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...
HIV Drug Makers Get Spooked by Possible Trump Cut, but Impact Looks Manageable
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
Healio7d
Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Investing2d
Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition
Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical powerhouse known for its groundbreaking HIV treatments, stands at a critical juncture as it navigates a changing landscape in the ...
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
The Independent10d
HIV prevention medication ‘could one day be a yearly jab’ – study suggests
The new study, published in The Lancet, found that a yearly injection lenacapavir, made by Gilead Sciences ... data show the potential for biomedical HIV prevention with a once-yearly dosing ...